The New Coronavirus 'Magic Drug' Stepped Off the Altar, WHO said that it has only been Proven Effective for Severely Patients

The World Health Organization announced that the latest research results on drugs involving new coronary pneumonia show that Redecive and others have little effect in preventing the death of patients with new coronary pneumonia or shortening the length of hospitalization. Dexamethasone is still the only effective medicine for critically ill patients of new coronary pneumonia. In other words, among the new coronavirus drugs publicly 'recommended' by U.S. President Trump, only Dexamethasone has been proven to be effective for severely ill patients.
 

This is not the first time that Dexamethasone has entered the public eye due to new coronary pneumonia. Earlier this month, the White House team of doctors revealed that Trump had received Dexamethasone treatment after he was admitted to the hospital for new coronary pneumonia.
 

On June 16  the British Ministry of Health announced that it would approve the use of Dexamethasone in the national medical system to treat patients with new coronavirus who need oxygen and use ventilators. A randomized clinical trial project for new coronavirus drugs supported by the British government has successively launched clinical trials on a variety of mature drugs such as dexamethasone. A research team led by the University of Oxford in the United Kingdom has conducted clinical trials on more than 2,000 patients with severe new coronavirus patients to use Dexamethasone. The results show that this drug can significantly reduce the death risk of new coronary patients who need to use ventilators by 35%; the risk of death of new coronary patients who need oxygen is also reduced by 20% after treatment.
 

The WHO also stated that Hydroxychloroquine, Lopinavir/Ritonavir and Interferon treatments have little effect in preventing deaths or shortening hospital stays in patients with new coronary pneumonia.
 

Hydroxychloroquine was originally used to treat malaria, and now it is often used to treat lupus erythematosus, rheumatoid arthritis, etc. Trump called it 'the biggest game-changing drug in the history of medicine' and has repeatedly recommended it publicly. On March 29, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) that allows chloroquine and hydroxychloroquine to be used to treat new coronary pneumonia. At the same time, researcher Hawult published a research paper saying that in a trial involving 36 people, hydroxychloroquine and azithromycin were used together to help treat new coronary pneumonia. The study also caused controversy due to the small number of participants, and the Hawult team subsequently launched a study involving 80 volunteers. The results showed that when hydroxychloroquine and azithromycin were used in combination, on the 7th day after treatment, 85% of patients turned negative by polymerase chain reaction (PCR), and 1 patient died and 3 patients were transferred to the intensive care unit. Insiders pointed out that the test alone cannot confirm the effectiveness and safety of hydroxychloroquine against new coronary pneumonia.
 

At a White House Covid-19 Response Working Group meeting in April, White House Senior Trade Advisor Peter Navarro and the top U.S. infectious disease expert Anthony Fauci staged an 'epic quarrel'. The focus of the dispute between the two parties was whether hydroxychloroquine is an effective against new coronary pneumonia and whether it is worth promoting.
 

"People's Hope" Remdesivir proved to be ineffective
Among the several drugs mentioned by the WHO this time, Redcivir is well-known, and Trump has also used the drug in his treatment. Remdesivir has been hoped since the beginning of the new crown pneumonia outbreak, and because of its original English name Remdesivir homophonic, it was called "the hope of the people" by domestic netizens.
 

Remdesivir is a nucleotide analogue of the American pharmaceutical company Gilead, which has broad-spectrum antiviral activity. It has shown its effect on a variety of emerging viral pathogens in in vitro and in vivo studies in animal models, including Egypt Bora virus, Marburg virus, Middle East respiratory syndrome (MERS) and atypical pneumonia (SARS) viruses. In vitro tests conducted by Gilead show that redecive is active against the new coronavirus.
 

Since the outbreak of the new coronary pneumonia, a number of clinical trials have been carried out worldwide to evaluate the safety and effectiveness of Remdesivir in the treatment of new coronary pneumonia. In April, an analysis of the interim results of a randomized controlled trial involving 1,063 patients in the United States showed that the recovery time of patients receiving Remdesivir was 32% faster than that of patients receiving placebo. However, according to the news released by the WHO, Remdesivir and others have little effect in preventing the death of patients with new coronary pneumonia or shortening the length of hospital stay.
 

Remdesivir has previously been approved in some countries and regions. Up to now, Remdesivir has been approved or authorized to varying degrees in more than 50 countries and regions based on previous research data for the treatment of new coronary pneumonia.

Disclaimer